Micafungin vials
Product Description
Xellia Pharmaceuticals ApS
-
DK -
2015On CPHI since
-
4Certificates
-
1000 - 4999Employees
Company types
Primary activities
.jpg)
Categories
Xellia Pharmaceuticals ApS
-
DK
-
2015On CPHI since
-
4Certificates
-
1000 - 4999Employees
Company types
Primary activities
More Products from Xellia Pharmaceuticals ApS (21)
-
Product Vancomycin hydrochloride (manufactured in Copenhagen, Denmark)
Vancomycin hydrochloride is a glycopeptide antibiotic active against a wide variety of Gram-positive bacteria, most important being staphylococci, including Staphylococcus aureus and Staphylococcus epidermidis (including heterogeneous methicillin-resistant strains), but also active against diphtheroid... -
Product Vancomycin hydrochloride (manufactured in Taizhou, China)
Vancomycin hydrochloride is a glycopeptide antibiotic active against a wide variety of Gram-positive bacteria, most important being staphylococci, including Staphylococcus aureus and Staphylococcus epidermidis (including heterogeneous methicillin-resistant strains), but also active against diphtheroid... -
Product Bacitracin vials
Bacitracin is comprised of a polypeptide complex and bacitracin A is the major component in this complex active against a variety of Gram-positive bacteria and a few Gram-negative bacteria, however only staphylococcal infections qualify for the systemic therapy.
Indi... -
Product Colistimethate sodium lyophilized vials
Colistimethate sodium is a prodrug of colistin, which is a mixture of polypeptide antibiotics active against Gram-negative bacteria, including Enterobacter aerogenes, Escherichia coli, Klebsiella pneumoniae and especially Pseudomonas aeruginosa.
Indication:&nbs... -
Product Daptomycin RT
Daptomycin is a lipopeptide antibacterial agent active against gram-positive bacteria.
Indication: Used in the treatment of complicated skin and skin structure/soft-tissue infections caused by susceptible isolates of gram-positive bacteria such as Staphylococcus aureus&nbs... -
Product Daptomycin vials
Daptomycin is a lipopeptide antibacterial agent active against Gram-positive bacteria.
Indication: Used in the treatment of complicated skin and skin structure/soft-tissue infections caused by susceptible isolates of Gram-positive bacteria such as Staphylococcus au... -
Product Polymyxin B vials
Polymyxin B is a mixture of the sulfates of polypeptide antibiotics active against Gram-negative bacteria.
Indication: Used in the treatment of patients with acute urinary, meningeal or blood-stream infections due to susceptible strains such as Pseudomonas aerugino... -
Product Vancomycin HCI vials
Vancomycin hydrochloride (HCI) is a glycopeptide antibiotic active against a wide variety of aerobic Gram-positive bacteria, most important being staphylococci, including Staphylococcus aureus and Staphylococcus epidermidis (including heterogeneous methicillin-resistant strains), but also active against di... -
Product Voriconazole vials
Voriconazole is a broad spectrum triazole antifungal agent.
Indication: Used in the treatment of patients with progressive, possibly life-threatening fungal infections such as candidaemia in non-neutropenic patients, invasive candidiasis in skin, abdomen, kidney, bladd... -
Product Colistimethate sodium dry-filled vials
Colistimethate sodium is a prodrug of colistin which is a mixture of polypeptide antibiotics active against Gram-negative bacteria, including Enterobacter aerogenes, Escherichia coli, Klebsiella pneumoniae and Pseudomonas aeruginosa.
Indication: Used in the treatment of patients with serious infectio... -
Product Vancomycin Injection, Ready to Use
Vancomycin hydrochloride is a glycopeptide antibiotic active against a wide variety of Gram-positive bacteria, most important being staphylococci, such as Staphylococcus aureus and Staphylococcus epidermidis (including susceptible methicillin-resistant strains), but also active against corynebacterium, ent... -
Product Amphotericin B
Amphotericin B is a mixture of polyenes active against a wide variety of fungi e.g. Aspergillus, Candida and Cryptococcus species.
Indication: Used in the treatment of severe, invasive, potentially life-threatening fungal infections (mycosis) typically in immunocompromised patients. q...
Xellia Pharmaceuticals ApS resources (2)
-
News Xellia Pharmaceuticals welcomes Michael Kocher as its new Chief Executive Officer
Copenhagen, Denmark, 2 October 2023 - Xellia Pharmaceuticals (‘Xellia’), a global leader in the manufacturing of specialty anti-infective treatments and critical care therapies, today welcomes Michael Kocher as its new Chief Executive Officer. With more than a decade of experience in commercial leadership roles at Novartis and Sandoz, Michael Kocher has significant expertise in the complexities of the global pharmaceutical landscape. His tenure at Sandoz, where he served as Global Head of Commercial Operations and subsequently as Global Head of B2B, underscored his pivotal role in transforming the company into a leading global partner within the industry. A native of Germany and a trained chemist, Michael Kocher's expertise and vision align with Xellia Pharmaceuticals' commitment to delivering anti-infective treatments and critical care therapies. -
Technical Data Xellia Corporate Introduction
Xellia Pharmaceuticals is a specialty pharmaceutical company developing,manufacturing and commercializing anti-infective treatments againstserious and often life-threatening bacterial and fungal infections. Xellia isa world-leading trusted supplier of several important established antiinfectivedrugs, comprising active pharmaceutical ingredients as well asfinished dosage forms, where the majority are injectable drug products.Headquartered in Copenhagen, Denmark and owned by Novo HoldingsA/S, Xellia Pharmaceuticals has more than 1800 employees globally.From state-of-the-art manufacturing sites in the U.S., China, Denmarkand Hungary to R&D sites in Norway and Croatia; Xellia Pharmaceuticalsexcels within innovative product development to deliver high qualityproducts to its customers.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance